Protein Summary
Cell surface protein involved in cell-cell-interactions via its interactions with neurexin family members. Plays a role in synapse function and synaptic signal transmission, and probably mediates its effects by recruiting and clustering other synaptic proteins. May promote the initial formation of synapses, but is not essential for this. In vitro, triggers the de novo formation of presynaptic structures. May be involved in specification of excitatory synapses. Required to maintain wakefulness quality and normal synchrony of cerebral cortex activity during wakefulness and sleep. This gene encodes a member of a family of neuronal cell surface proteins. Members of this family may act as splice site-specific ligands for beta-neurexins and may be involved in the formation and remodeling of central nervous system synapses. [provided by RefSeq, Jul 2008]
- ENST00000361589
- ENSP00000354541
- ENSG00000169760
- ENST00000457714
- ENSP00000392500
- KIAA1070
- NL1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 0.98 | ||
kinase perturbation | 0.84 | ||
cellular component | 0.75 | ||
protein domain | 0.73 | ||
cell type or tissue | 0.69 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 138.74 (req: < 5)
Gene RIFs: 29 (req: <= 3)
Antibodies: 268 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 138.74 (req: >= 5)
Gene RIFs: 29 (req: > 3)
Antibodies: 268 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 60
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0